Bank of America’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-78,361
| Closed | -$179K | – | 8482 |
|
|
2024
Q2 | $179K | Sell |
78,361
-300,650
| -79% | -$1.15M | ﹤0.01% | 5945 |
|
|
2024
Q1 | $1.64M | Buy |
379,011
+99,552
| +36% | +$347K | ﹤0.01% | 4580 |
|
|
2023
Q4 | $852K | Sell |
279,459
-8,806
| -3% | -$16.5K | ﹤0.01% | 5103 |
|
|
2023
Q3 | $415K | Sell |
288,265
-32,081
| -10% | -$62.1K | ﹤0.01% | 5439 |
|
|
2023
Q2 | $798K | Sell |
320,346
-283,072
| -47% | -$773K | ﹤0.01% | 4940 |
|
|
2023
Q1 | $1.62M | Buy |
603,418
+347,052
| +135% | +$1.67M | ﹤0.01% | 4533 |
|
|
2022
Q4 | $1.39M | Sell |
256,366
-79,588
| -24% | -$667K | ﹤0.01% | 4584 |
|
|
2022
Q3 | $4.2M | Buy |
335,954
+80,901
| +32% | +$924K | ﹤0.01% | 3515 |
|
|
2022
Q2 | $1.26M | Sell |
255,053
-107,520
| -30% | -$595K | ﹤0.01% | 4701 |
|
|
2022
Q1 | $2.76M | Sell |
362,573
-10,127
| -3% | -$96K | ﹤0.01% | 4261 |
|
|
2021
Q4 | $3.8M | Buy |
372,700
+99,335
| +36% | +$1.27M | ﹤0.01% | 3933 |
|
|
2021
Q3 | $3.67M | Sell |
273,365
-68,273
| -20% | -$1.11M | ﹤0.01% | 3870 |
|
|
2021
Q2 | $7.5M | Buy |
341,638
+70,500
| +26% | +$1.57M | ﹤0.01% | 3112 |
|
|
2021
Q1 | $6.52M | Buy |
271,138
+3,824
| +1% | +$88.9K | ﹤0.01% | 3130 |
|
|
2020
Q4 | $4.81M | Sell |
267,314
-17,162
| -6% | -$256K | ﹤0.01% | 3167 |
|
|
2020
Q3 | $3.29M | Buy |
284,476
+17,927
| +7% | +$296K | ﹤0.01% | 3291 |
|
|
2020
Q2 | $6.47M | Buy |
266,549
+3,972
| +2% | +$65.7K | ﹤0.01% | 2623 |
|
|
2020
Q1 | $2.89M | Sell |
262,577
-9,219
| -3% | -$172K | ﹤0.01% | 3181 |
|
|
2019
Q4 | $7.18M | Sell |
271,796
-541
| -0.2% | -$12.7K | ﹤0.01% | 2880 |
|
|
2019
Q3 | $6.2M | Sell |
272,337
-27,312
| -9% | -$861K | ﹤0.01% | 2989 |
|
|
2019
Q2 | $9.19M | Sell |
299,649
-146,328
| -33% | -$3.08M | ﹤0.01% | 2638 |
|
|
2019
Q1 | $7.4M | Buy |
445,977
+192,398
| +76% | +$3.65M | ﹤0.01% | 2776 |
|
|
2018
Q4 | $4.86M | Buy |
253,579
+281
| +0.1% | +$10.5K | ﹤0.01% | 3016 |
|
|
2018
Q3 | $13.2M | Sell |
253,298
-14,173
| -5% | -$773K | ﹤0.01% | 2179 |
|
|
2018
Q2 | $11.6M | Buy |
267,471
+11,877
| +5% | +$509K | ﹤0.01% | 2308 |
|
|
2018
Q1 | $9.47M | Buy |
255,594
+218
| +0.1% | +$5.82K | ﹤0.01% | 2465 |
|
|
2017
Q4 | $5.07M | Buy |
255,376
+255,011
| +69,866% | +$5.48M | ﹤0.01% | 3107 |
|
|
2017
Q3 | $9K | Buy |
+365
| New | +$6.74K | ﹤0.01% | 6589 |
|
Bank of America's GTHX Position: Q3 2024 in Review
Bank of America sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 78,361 shares — an estimated $179K sold.
Bank of America first reported a position in GTHX in Q3 2017 and held it in 28 quarters. The position peaked at $13.2M in Q3 2018. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Bank of America reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Bank of America sold 78,361 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $179K.
- Bank of America first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2017 and held it in 28 quarters.
- Bank of America's G1 Therapeutics, Inc. Common Stock position peaked at $13.2M in Q3 2018.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Bank of America's 13F filing for Q3 2024, filed 14 Nov 2024.